Alp Invest Partners B.V. Madrigal Pharmaceuticals, Inc. Transaction History

Alp Invest Partners B.V.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$212.22 - $292.96 $8.98 Million - $12.4 Million	-42,298 Reduced 50.0%	42,297 $8.98 Million
Q2 2024 Aug 09, 2024	SELL	$193.33 - $291.99 $4.09 Million - $6.18 Million	-21,149 Reduced 20.0%	84,595 $23.7 Million
Q1 2024 May 03, 2024	SELL	$171.37 - $283.23 $18.1 Million - $29.9 Million	-105,744 Reduced 50.0%	105,744 $28.2 Million
Q4 2023 Feb 02, 2024	BUY	$120.4 - $237.13 $25.5 Million - $50.2 Million	211,488 New	211,488 $48.9 Million

335

22.3M

960K

940K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.75B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Alp Invest Partners B.V., based on Form 13F filings with the SEC.

Stay updated on Alp Invest Partners B.V. with notifications on news.